Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Innovent Biologics
IVBIY
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$22.00
0
0.00%
Last update: Sep 3, 9:40 AM
15 minutes delayed
Get Report
Comment
Innovent Biologics (IVBIY) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Innovent Biologics (OTC:IVBIY) Stock
Innovent Biologics Stock (OTC: IVBIY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, September 12, 2024
Reported Earlier, Innovent's Phase 3 DREAMS-2...
Benzinga Newsdesk
Tuesday, September 10, 2024
Reported Earlier, Innovent Presents Update On...
Benzinga Newsdesk
Wednesday, September 04, 2024
Reported Earlier, Innovent Receives FDA Fast ...
Benzinga Newsdesk
Tuesday, April 02, 2024
HUTCHMED And Innovent Announce NDA Acceptance...
Benzinga Newsdesk
Wednesday, March 27, 2024
Reported Earlier, Innovent Dosed First Partic...
Benzinga Newsdesk
Tuesday, March 05, 2024
Innovent And AnHeart Therapeutics Announce Th...
Benzinga Newsdesk
Friday, March 01, 2024
Innovent Announces First Participant Dosed In...
Benzinga Newsdesk
Thursday, December 28, 2023
Innovent And Xuanzhu Collaborate On A Clinica...
Benzinga Newsdesk
Monday, December 18, 2023
Innovent Biologics Publishes Mazdutide (IBI36...
Benzinga Newsdesk
Thursday, March 24, 2022
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
Vandana Singh
Friday, February 11, 2022
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
Vandana Singh
Tuesday, September 28, 2021
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
Vandana Singh
Friday, August 27, 2021
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Vandana Singh
Monday, August 16, 2021
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Vandana Singh
Friday, August 06, 2021
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Vandana Singh
Friday, July 09, 2021
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
Vandana Singh
Thursday, June 03, 2021
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
Vandana Singh
Tuesday, May 18, 2021
Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA
Vandana Singh
